Yazar "Abali, Huseyin" için Tıp Fakültesi / Faculty of Medicine listeleme
-
Prognostic Role of fox-p3 Positive T-Regulatory Cells in Curatively Resected NSCLC Other than Stage IA
Kose, Fatih; Besen, Ayberk; Findikcioglu, Alper; Canbolat, Tuba; Ozdemir, Yurday; Sedef, Ali M.; Mertsoylu, Huseyin; Sumbul, Ahmet T.; Ozyilkan, Ozgur; Abali, Huseyin (2015) -
Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?
Urun, Yuksel; Yasar, H. Arzu; Turna, Hande; Kilickap, Saadettin; Sezer, Ahmet; Oksuzoglu, Berna; Ozdemir, Nuriye; Sendur, M. A. Nahit; Abali, Huseyin (2019) -
A Study of the Combination of Oxaliplatin, Capecitabine, and Herceptin (Trastuzumab) And Chemoradiotherapy in The Adjuvant Setting in Operated Patients with HER2+Gastric Or Gastro-Esophageal Junction Cancer (TOXAG Study).
Abali, Huseyin; Yalcin, Suayib; Onal, Huseyin Cem; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye; Mertsoylu, Huseyin; Artac, Mehmet; Camci, Celalettin; Karabulut, Bulent; Basal, Fatma Bugdayci; Budakoglu, Burcin; Sendur, Mehmet Ali Nahit; Goktas, Burce; Ozdener, Fatih; Calisgan, Arzu (2016) -
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemo-Radiotherapy in the Adjuvant Setting in Operated Patients with HER2+Gastric or Gastroesophageal Junction Cancer (TOXAG Study)
Abali, Huseyin; Yalcin, Suayib; Onal, Cem; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye; Mertsoylu, Huseyin; Artac, Mehmet; Camci, Celaletdin; Karabulut, Bulent; Basal, Fatma Bugdayci; Budakoglu, Burcin; Sendur, Mehmet Ali Nahit; Goktas, Burce; Ozdener, Fatih; Baygul, Arzu (2018) -
Who Benefits Most from Adjuvant Interferon Treatment for Melanoma?
Gogas, Helen; Abali, Huseyin; Ascierto, Paolo A.; Demidov, Lev; Pehamberger, Hubert; Robert, Caroline; Schachter, Jacob; Eggermont, Alexander M. M.; Hauschild, Axel; Espinosa, Enrique (2015)Metastatic melanoma has a poor prognosis; the median survival for patients with stage IV melanoma ranges from 8 to 18 months after diagnosis. Interferon-a provides significant improvement in disease-free survival at the ...